The FDA approved Kynamro with a Risk Evaluation and Mitigation Strategy (REMS) with elements to assure safe use, including prescriber and pharmacy certification, and documentation of safe-use conditions, which requires a prescription authorization form for eachnew prescription.
The new guidelines clarify that written parental consent is not needed for each activity and encourage schools to use a new one-off consent form signed once when a child starts at a school.